Hosted on MSN1mon
Regeneron expands eye care focus with Oxular buyoutRegeneron Pharmaceuticals (NASDAQ:REGN), the maker of eye disease therapy Eylea, has acquired Oxular, a U.K.-based biotech drug developer focused on ophthalmology. While neither company formally ...
TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported fourth-quarter earnings of $917.7 million. On a per-share basis, the Tarrytown ...
(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with Regeneron Pharmaceuticals. The supply agreement supports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback